RxDoctor Payments Data

David Okada, MD

Clinical Cardiac Electrophysiology · Tulsa, OKNPI 1366880825

Payments from drug & device makers

What this record shows

This record is dominated by grants: $14,208 of the $16,118 with a category attached, or 88.2%. Medtronic accounts for 68.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $8,792 and has fallen 97.1% since, to $251 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in OK, where the typical reported total is $22,745.

$16,118in general payments, 2019–2025

Across 61 payments — averaging $264.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$4K
  • Biosense Webster, Inc.$562
  • Boston Scientific$453
  • Cardiva Medical, Inc.$96
  • Abiomed$44
  • plus $285 from 11 others

What the payments were for

  • Grants$14,20888%
  • Food & beverage$1,4869%
  • Education$4233%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,118 in reported general payments places this provider in the 25th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

See all clinical cardiac electrophysiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$239,898
Medicare patients
1,828
Services billed
3,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$182,069
XareltoRivaroxaban76$88,530
MultaqDronedarone Hcl110$79,910
Flecainide Acetate132$4,870
Diltiazem 12hr ErDiltiazem Hcl22$3,254
Metoprolol Succinate132$2,417
Amiodarone Hcl121$2,364
Metoprolol Tartrate80$883
Nadolol13$653
Pantoprazole Sodium65$562
Potassium Chloride14$337
Digoxin15$335
Propranolol Hcl ErPropranolol Hcl19$324
SotalolSotalol Hcl14$303
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$182,069222 claims
Johnson & JohnsonXarelto$18$88,53076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

Other clinical cardiac electrophysiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →